Contact Dermatitis

Cover image for Vol. 76 Issue 3

Edited By: Wolfgang Uter

Impact Factor: 5.692

ISI Journal Citation Reports © Ranking: 2015: 2/61 (Dermatology); 3/25 (Allergy)

Online ISSN: 1600-0536

Author Guidelines

Online submission of manuscripts 

Authors are required to submit manuscripts online via ScholarOne Manuscript. Manuscripts must be submitted as Word (doc) files, charts as Excel (xls) files and figures submitted as high resolution JPEG files. Do not embed figures within the main text; append them as separate files. 

Authors for whom English is a second language may choose to have their manuscript professionally edited before submission. We are unable to accept any Manuscript submitted in inaccessible English or in a form unsuitable for effective peer review ( Authors submitting a paper do so on the understanding that the work has not been published before, is not being considered for publication elsewhere and has been read and approved by all authors.

Contact Dermatitis employs a plagiarism detection system. By submitting your manuscript to this journal you accept that your manuscript may be screened for plagiarism against previously published works. Prior to submission, authors should carefully check the Ethical guidelines document available here.

If you need further instructions for electronic submission of manuscripts please contact the Editor-in-Chief:

Wolfgang Uter
Dept. of Medical Informatics, Biometry and Epidemiology
Univ. of Erlangen-Nürnberg
91054 Erlangen

Original papers and review articles should, in most cases, not exceed 8 printed pages (approx. 700 words per printed page). Additional pages must be paid for by the authors at a current rate of GBP140 per page (does not apply to review articles).

Contact Dermatitis accepts original articles, review articles, ‘Contact Points’, contributions addressing 'Education and Debate' and letters to the editor.

Submission of revisions

If as outcome of the review process a revision is recommended, the revised manuscript should normally be submitted by the authors within 6 weeks. It is mandatory that all changes to the original manuscript (deletions, insertions, corrections) are highlighted, e.g. by using the 'track changes' function of the word processor. A separate point-by-point reply to reviewers' comments is encouraged, but not a substitute for above. Re-submissions not complying with this requirement will be immediately returned to the author.


For all submissions:

Title page containing:

(1)   Concise informative title;

(2)   Name(s) of author(s). Family names should be underlined;

(3)   Name of department(s)/institution(s) to which the work is attributed;

(4)   Name and address of author for correspondence about the manuscript; an email address must be provided;

(5)   Disclosures: failure to disclose potential conflicts of interests will result in rejection of the manuscript.

a.       Statement of all funding that supported the work must be clearly indicated;

b.      All conflicts of interests must be given [Each author is responsible for disclosing all financial and personal relationships that might be perceived by others as biasing their work. Authors MUST state whether potential conflicts exist or not. This will be recorded in the publication];

(6)   Author contributions.

a.       Each author should have participated sufficiently to take public responsibility for appropriate portions of the work and consented to the final, submitted version. Each author's contributions need to be clearly stated. All other individuals should be named in the Acknowledgements (see below);

(7)   If the title exceeds 40 characters (letters and spaces) a running head of no more than 40 characters.

For original and review articles:

Summary and key words - The summary should not exceed 200 words. Original articles should have a structured abstract, comprising the five headings:

  1. Background,
  2. Objectives,
  3. Patients/Materials/Methods,
  4. Results,
  5. Conclusions.

Below the abstract, provide 3-8 key words or phrases.

Introduction - Present the background briefly, but do not review the subject extensively. Give only pertinent, current (if possible) references. State the specific questions you want to answer.

Patients and Methods/Materials and Methods - Describe selection of patients or experimental animals, including controls. Do not use patients' names or hospital numbers.

Identify patch test materials (supplier, dilution, vehicle), chambers used, application period and days of readings (use D2, D4 not 48, 96hrs etc).

Identify methods, apparatus (manufacturer's name and address) and procedures in sufficient detail to allow other workers to reproduce the results. Provide references and brief descriptions of methods that have been published. When using new methods, evaluate their advantages and limitations.

Identify drugs, chemicals and consumer products (including cosmetics unless a specific reason for non-disclosure is given) including generic name, dosage and route(s) of administration.

Indicate whether the procedures were approved by a properly constituted Ethics Committee in your country, or in accordance with the current Helsinki Declaration. Drug trials must be logged on a public register, the register and the registration number must be stated in the text.

Results - Present results in logical sequence in tables and illustrations. In the text, explain, emphasise or summarise the most important observations. Units of measurement must be expressed in accordance with the Système International d'Unités (SI Units).

When appropriate, data should be statistically evaluated and the appropriateness of the statistical methodology explained. Estimates (proportions, means, risk quotients etc.) should include confidence intervals. Authors are encouraged to seek advice from a statistician.

Discussion - Do not repeat in detail data given in the Results section. Emphasise the new and important aspects of the study. Relate the observations to other relevant studies. On the basis of your findings (and those of others), discuss possible implications/conclusions. Limitations, as well as strengths, of your study should be discussed, however, avoiding sweeping generalisations. When stating a new hypothesis, clearly identify it as such.

Acknowledgements - Acknowledge only persons who have made substantive contributions to the study. Authors are responsible for obtaining written permission from everyone acknowledged by name because readers may infer their endorsement of the data and conclusions.

Tables - Tables should be numbered consecutively with Arabic numerals. Type each table on a separate sheet, with titles and footnotes making them self-explanatory.

Figures (illustrations, chemical structures and photographs) - should clarify the text and their numbers be kept to a minimum. Details must be sufficient to retain their clarity after reduction of size. Colour illustrations will be accepted free of charge.

Chemical structures should be produced with a chemical structure drawing program (e.g., ChemSketch) and conform to the American Chemical Society settings.

Photographs - When there is any chance that a person may be identified from a picture, legend or other accompanying text, Contact Dermatitis requires the individual's signed consent to publication. Editors may choose to publish the photograph on the front page of the journal. Pictures with black bands across the eyes are discouraged.

Legends - Figure legends should allow interpretation of the figures without reference to the main text; they should appear according to their order of appearance in the text.

References - Number references consecutively in the order in which they are first mentioned in the text. Identify references in text, tables and legends by Arabic numerals (in parentheses). All publications cited, and only these, must be listed at the end of the paper. References should follow the following style examples:

1. Giwercman C, Lerbaek A, Bisgaard H, Menné T. Classification of atopic hand eczema and the filaggrin mutations. Contact Dermatitis 2008: 59: 257-260.

2. Agner T, Menné T. Individual predisposition to irritant and allergic contact dermatitis. In: Contact Dermatitis, 4th edition, Frosch P J, Menné T, Lepottevin J-P (eds.): Berlin Heidelberg, Springer-Verlag, 2006: 127-134.

3. European Commission, Scientific Committee on Consumer Products. Opinion on Oak moss /Tree moss (sensitisaton only), 2008. Available at: (last accessed 01 December 2008).

Ensure that accents are included on names (e.g. Søsted H. Menné T. not Sosted H. Menne T). List up to 4 authors; if more than 4, list the first 3 followed by et al.

Other Requirements

Abbreviations and symbols - All units must be metric.

Unfamiliar abbreviations must be defined when first used.

Avoid acronyms and excessive use of unnecessary abbreviations (e.g., atopic dermatitis not AD, hand eczema not HE, allergic contact dermatitis not ACD).

Do not use Roman numerals in the text.

In decimal fractions a decimal point, and not a comma, must be used. The minus sign is shown as --.

Use a space between digits to separate thousands (eg. million: 1 000 000). Confidence Intervals should be in the format 95%CI: 1.23-4.56 unless there is a negative value, in which case 95%CI: -1.23 to 4.56 or, 95%CI: -4.56 to -1.23. Please round %, RR, OR etc. to 1 decimal place or 2 significant figures, as appropriate, and give p-values with 2 significant figures; if p < 0.001, write p < 0.001 (p for p-value all in italics).

Nomenclature - All units must be defined.

Units of measurement must be SI Units.

Chemical names and botanical extracts should be INCI, if available (, and in preference to other common names; CAS numbers should be provided, if appropriate (e.g., 2-bromo-2-nitropropane-1,3-diol (bronopol; CAS_no. 52-51-7)).

For drugs, the International Non-proprietary Name (INN) should be used (

CONTACT POINTS - Short papers not exceeding 600 words including references, 400 words with a table or figure included may be accepted for publication if they serve to promote communication between clinicians and research workers.

In contrast to Original Articles, contributes to this section will not undergo peer review but will be assessed by the editorial team. Contact points should include:

-          Title page see above;

-           Key words - 3-18;

-          Introduction - Present the background briefly, but do not review the subject extensively;

-          Case Report or Methods/Materials and Results;

-          Discussion - Emphasise the new and important aspects.

Figures, Abbreviations and Nomenclature should conform to the instructions for Manuscripts see above.


Note to NIH Grantees
Pursuant to NIH mandate, Wiley-Blackwell will post the accepted version of contributions authored by NIH grant-holders to PubMed Central upon acceptance. This accepted version will be made publicly available 12 months after publication. For further information, see


If your paper is accepted, the author identified as the formal corresponding author for the paper will receive an email prompting them to login into Author Services; where via the Wiley Author Licensing Service (WALS) they will be able to complete the license agreement on behalf of all authors on the paper.

For authors signing the copyright transfer agreement

If the OnlineOpen option is not selected the corresponding author will be presented with the copyright transfer agreement (CTA) to sign. The terms and conditions of the CTA can be previewed in the samples associated with the Copyright FAQs below:

CTA Terms and Conditions

For authors choosing OnlineOpen

If the OnlineOpen option is selected the corresponding author will have a choice of the following Creative Commons License Open Access Agreements (OAA):

Creative Commons Attribution License OAA

Creative Commons Attribution Non-Commercial License OAA

Creative Commons Attribution Non-Commercial -NoDerivs License OAA

To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Services and Wiley Open Access.

If you select the OnlineOpen option and your research is funded by The Wellcome Trust and members of the Research Councils UK (RCUK) or the Austrian Science Fund (FWF) you will be given the opportunity to publish your article under a CC-BY license supporting you in complying with your Funder requirements. For more information on this policy and the Journal’s compliant self-archiving policy please click here.

OnlineOpen - is available to authors of primary research articles who wish to make their article available to non-subscribers on publication, or whose funding agency requires grantees to archive the final version of their article. With OnlineOpen, the author, the author's funding agency, or the author's institution pays a fee to ensure that the article is made available to non-subscribers upon publication via Wiley InterScience, as well as deposited in the funding agency's preferred archive. For the full list of terms and conditions, click here.

Any authors wishing to send their paper OnlineOpen will be required to complete the payment form available from our website.

Prior to acceptance there is no requirement to inform an Editorial Office that you intend to publish your paper OnlineOpen if you do not wish to. All OnlineOpen articles are treated in the same way as any other article. They go through the journal's standard peer-review process and will be accepted or rejected based on their own merit.

Proofs - Manuscripts may be revised within the editorial office. Only in case of extensive corrections will the manuscript be returned to the authors for final approval.

The corresponding author will receive an email alert containing a link to a web site. A working email address must therefore be provided for the corresponding author. Further instructions will be sent with the proof.

Author Services:

Offprints/reprints - Corresponding authors will automatically receive a PDF offprint by email.

Early View - Contact Dermatitis is covered by Blackwell Publishing's Early View service.